SyntheticMR announced today that they have established a subsidiary in India. This will be the company’s second subsidiary, following the establishment of a USA subsidiary in 2019, and aims to expand SyntheticMR’s market and accelerate strategic initiatives in India and the South East Asia region.

The subsidiary will be led by Deepak Sharma, who has been managing the region for SyntheticMR since 2019. He has more than 20 years of international experience in the healthcare domain.

The SyntheticMR India subsidiary employs more than 10 people across India and supports a user base of over 20 institutions, including leading centers such as DY Patil, Mahajan Imaging, and Fortis Mumbai. The SyntheticMR subsidiary will also strengthen collaborations with strategic partners on a regional level.
“India and South East Asia is a large market with a high potential for growth, where we see a great market fit for our products. Establishing a local subsidiary represents a significant step for us as an organization and will support us as we continue to execute on our mission to set a new standard of care in quantitative imaging,” says Ulrik Harrysson, CEO SyntheticMR AB.


About SyntheticMR AB
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden.

Business Affairs Homepage